Actively Recruiting
Phase 2 Trial of Riluzole to Prevent Cognitive Problems in Adults With Cancer Receiving Chemotherapy
Led by University of California, Irvine · Updated on 2026-03-03
24
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating riluzole to see if it can help prevent cognitive problems in people with cancer who are receiving chemotherapy. This study is a phase II, randomized, double-blinded, placebo-controlled pilot trial focused on patients undergoing anthracycline- or platinum-based chemotherapy. The trial aims to understand how riluzole affects brain function during cancer treatment. Participants are randomly assigned to one of two groups one group takes 50 mg of riluzole twice daily for up to six months, while the other group receives a placebo that looks like riluzole, taken with the same schedule. Both treatments are given by mouth. The study monitors patients over a six-month period to compare effects between the riluzole and placebo groups. During the trial, participants will complete questionnaires and computerized tests to assess cognitive function, even if they have visual impairments or certain neurological conditions. Researchers will also measure changes in brain-derived neurotrophic factor BDNF levels, which relate to brain health. Safety and overall health will be monitored, and the study lasts for six months from the start of treatment.
CONDITIONS
Brief Title
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
Research Team
C
Chao Family Comprehensive Cancer Center University of California, Irvine
U
University of California Irvine Medical
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
